RA Capital Management L.P. Has $207.54 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• RA Capital Management L.P. increased its stake in NewAmsterdam Pharma by 14.6%, making it the 5th largest position in their portfolio, now owning about $207 million worth of the company.
• Insider trading reveals significant sales, including COO Douglas F. Kling selling 100,000 shares for approximately $1.93 million, leading to a substantial decrease in his ownership.
• NewAmsterdam Pharma reported quarterly earnings with a positive EPS of ($0.15), surpassing consensus estimates and generating $19.15 million in revenue compared to the expected $1.44 million.

RA Capital Management L.P. boosted its stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 14.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,138,938 shares of the company's stock after acquiring an additional 1,293,938 shares during the quarter. NewAmsterdam Pharma makes up approximately 3.5% of RA Capital Management L.P.'s holdings, making the stock its 5th biggest holding. RA Capital Management L.P. owned about 9.23% of NewAmsterdam Pharma worth $207,544,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Quarry LP bought a new stake in NewAmsterdam Pharma during the 1st quarter worth about $25,000. GF Fund Management CO. LTD. acquired a new position in NewAmsterdam Pharma during the 4th quarter valued at about $50,000. Mirae Asset Global Investments Co. Ltd. lifted its position in NewAmsterdam Pharma by 19.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock valued at $80,000 after purchasing an additional 596 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in NewAmsterdam Pharma by 130.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock valued at $123,000 after purchasing an additional 3,390 shares during the period. Finally, Avanza Fonder AB acquired a new position in NewAmsterdam Pharma during the 1st quarter valued at about $127,000. Institutional investors own 89.89% of the company's stock.

Insiders Place Their Bets

In related news, COO Douglas F. Kling sold 51,043 shares of the stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $21.10, for a total transaction of $1,077,007.30. Following the completion of the sale, the chief operating officer directly owned 44,000 shares of the company's stock, valued at approximately $928,400. This represents a 53.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Louise Frederika Kooij sold 18,073 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $25.09, for a total value of $453,451.57. Following the sale, the chief accounting officer directly owned 15,000 shares of the company's stock, valued at approximately $376,350. The trade was a 54.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders acquired 12,835 shares of company stock valued at $248,134 and sold 274,954 shares valued at $5,899,406. 20.84% of the stock is owned by corporate insiders.

NewAmsterdam Pharma Trading Up 5.2%

Shares of NASDAQ:NAMS traded up $1.34 during mid-day trading on Friday, reaching $27.00. The stock had a trading volume of 1,570,503 shares, compared to its average volume of 806,032. The firm has a market cap of $3.04 billion, a PE ratio of -16.67 and a beta of -0.01. The firm has a 50 day simple moving average of $22.98 and a two-hundred day simple moving average of $20.55. NewAmsterdam Pharma Company N.V. has a twelve month low of $14.06 and a twelve month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. The business had revenue of $19.15 million for the quarter, compared to the consensus estimate of $1.44 million. On average, equities analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on NAMS shares. The Goldman Sachs Group started coverage on shares of NewAmsterdam Pharma in a research report on Thursday, July 17th. They set a "neutral" rating and a $27.00 target price on the stock. Needham & Company LLC restated a "buy" rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Wells Fargo & Company started coverage on shares of NewAmsterdam Pharma in a research report on Monday, August 25th. They set an "overweight" rating and a $45.00 target price on the stock. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. Finally, Royal Bank Of Canada increased their price target on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $41.55.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.